As Biotechnology companies, Protalix BioTherapeutics Inc. (NYSEAMERICAN:PLX) and BioLineRx Ltd. (NASDAQ:BLRX) are our subject to contrast. And more specifically their analyst recommendations, profitability, risk, dividends, earnings and valuation, institutional ownership.
Valuation and Earnings
Table 1 demonstrates Protalix BioTherapeutics Inc. and BioLineRx Ltd.s gross revenue, earnings per share (EPS) and valuation.
Profitability
Table 2 represents Protalix BioTherapeutics Inc. (NYSEAMERICAN:PLX) and BioLineRx Ltd. (NASDAQ:BLRX)s return on equity, net margins and return on assets.
Institutional & Insider Ownership
The shares of both Protalix BioTherapeutics Inc. and BioLineRx Ltd. are owned by institutional investors at 9.7% and 27.13% respectively. Insiders held 6.23% of Protalix BioTherapeutics Inc. shares. Comparatively, 3.46% are BioLineRx Ltd.s share held by insiders.
Performance
Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.
For the past year Protalix BioTherapeutics Inc. has 20.55% stronger performance while BioLineRx Ltd. has -39.48% weaker performance.
Summary
Protalix BioTherapeutics Inc. beats BioLineRx Ltd. on 5 of the 7 factors.
Protalix BioTherapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system in Israel and internationally. The company offers taliglucerase alfa for injection, which is an enzyme replacement therapy for the long-term treatment of adult patients with a confirmed diagnosis of type 1 Gaucher disease. Its product pipeline comprises PRX-102, a therapeutic protein candidate, which is in phase III clinical trials to treat Fabry diseases; PRX-110, a proprietary plant cell recombinant form of human deoxyribonuclease I that is in phase II clinical trials to treat cystic fibrosis; and OPRX-106, an oral anti TNF product candidate, which is in Phase II clinical trial for the treatment of ulcerative colitis. Protalix BioTherapeutics, Inc. was founded in 1993 and is based in Karmiel, Israel.
BioLineRx Ltd., a clinical stage biopharmaceutical development company, engages in identifying, in-licensing, and developing therapeutic candidates that address unmet medical needs. Its development pipeline consists of clinical-stage therapeutic candidates, which include BL-8040, a novel peptide for the treatment of multiple cancer and hematological indications; AGI-134, an immunotherapy treatment in development for multiple solid tumors; and BL-5010, a customized, proprietary, pen-like applicator containing a novel, acidic, aqueous solution as a medical device for the non-surgical removal of benign skin lesions. The companys other therapeutic candidates comprise BL-1040, a novel, resorbable polymer solution for use in the prevention of ventricular remodeling that may occur in patients who have suffered an acute myocardial infarction; BL-9020, which is a novel monoclonal antibody treatment designed to prevent immune-mediated destruction of insulin-producing beta cells in the pancreas; BL-1210, a drug candidate intended for the treatment of liver fibrosis, primarily non- alcoholic steatohepatitis; BL-1220, an orally administered, novel composition of sodium alginate intended as a novel treatment for various liver failure conditions; and BL-1230, a cannabinoid receptor type 2 intended as a novel anti-inflammatory treatment for dry eye syndrome. The company has strategic collaborations with Novartis Pharma AG; Merck; MD Anderson Cancer Center to investigate the combination of BL-8040 with Keytruda (pembrolizumab) in pancreatic cancer; Genentech Inc. to investigate the combination of BL-8040 and Genentechs Atezolizumab in various Phase Ib studies for multiple solid tumor indications and acute myeloid leukemia. BioLineRx Ltd. was founded in 2003 and is headquartered in Modiin, Israel.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.
See the rest here:
Comparison of Protalix BioTherapeutics Inc. (PLX) and BioLineRx Ltd. (NASDAQ:BLRX) - MS Wkly
- Managing Right Ventricular Failure in PAH: An Algorithmic Approach | Advances in ... - April 13th, 2018 [April 13th, 2018]
- What Is the Ejection Fraction? - Verywell Health - May 12th, 2018 [May 12th, 2018]
- Ventricular septal defect - Wikipedia - June 21st, 2018 [June 21st, 2018]
- Heart Failure Medication: Beta-Blockers, Alpha Activity ... - July 7th, 2018 [July 7th, 2018]
- Acute Management of Pulmonary Embolism - American College ... - July 17th, 2018 [July 17th, 2018]
- Ventricular Remodeling | Profiles RNS - July 24th, 2018 [July 24th, 2018]
- Left ventricular hypertrophy - Wikipedia - August 20th, 2018 [August 20th, 2018]
- Ventricular Remodeling Surgery (SVR) - September 24th, 2018 [September 24th, 2018]
- Left Ventricular Remodeling in Heart Failure | JACC ... - November 25th, 2018 [November 25th, 2018]
- Ventricular dysfunction in heart failure - Britannica.com - December 25th, 2018 [December 25th, 2018]
- TIMI Study Group - LEADERSHIP - January 31st, 2019 [January 31st, 2019]
- Ventricular Remodeling Procedure | Main Line Health ... - February 24th, 2019 [February 24th, 2019]
- BioLineRx Ltd. (BLRX)'s Financial Results Comparing With Coherus BioSciences Inc. (NASDAQ:CHRS) - Stocks Beat - September 18th, 2019 [September 18th, 2019]
- Reviewing Aeterna Zentaris Inc. (AEZS)'s and BioLineRx Ltd. (NASDAQ:BLRX)'s results - Stocks Beat - September 18th, 2019 [September 18th, 2019]
- Karuna Therapeutics Inc. (KRTX) and BioLineRx Ltd. (NASDAQ:BLRX) Comparing side by side - Stocks Beat - September 18th, 2019 [September 18th, 2019]
- Arbutus Biopharma Corporation (ABUS)'s Financial Results Comparing With BioLineRx Ltd. (NASDAQ:BLRX) - The EN Herald - September 18th, 2019 [September 18th, 2019]
- Cardiac Dimensions touts Carillon TMVR study - Mass Device - September 18th, 2019 [September 18th, 2019]
- New PROVE-HF Data May Reassure Clinicians of Sacubitril/Valsartan Benefit in HFrEF - TCTMD - September 18th, 2019 [September 18th, 2019]
- Cardiac Restoration Systems Market Will Make a Huge Impact in Near Future - Wolf Mirror - September 18th, 2019 [September 18th, 2019]
- Reduce Fmr Study Shows Cardiac Dimensions' Carillon System Significantly Improves Mitral Regurgitation And Slows Worsening Of Heart Failure - TCTMD - September 18th, 2019 [September 18th, 2019]
- Heart Failure Society of America 2019: Virtual Visits, Spironolactone Issues, and Reasons to Worry - DocWire News - September 18th, 2019 [September 18th, 2019]
- LV Reverse Remodeling Not Improved by SGLT-2 Inhibitor - DocWire News - September 18th, 2019 [September 18th, 2019]
- BioLineRx Ltd. (BLRX)'s Financial Results Comparing With Soligenix Inc. (NASDAQ:SNGX) - CryptoCoinsTribune - September 22nd, 2019 [September 22nd, 2019]
- Biolinerx LTD. American Depositary Shares (NASDAQ:BLRX) Could Burn Your Long Portfolio After More Shorts - The MAK Daily - September 22nd, 2019 [September 22nd, 2019]
- Reviewing BioLineRx Ltd. (BLRX)'s and Dicerna Pharmaceuticals Inc. (NASDAQ:DRNA)'s results - CryptoCoinsTribune - September 22nd, 2019 [September 22nd, 2019]
- Contrasting of BioLineRx Ltd. (BLRX) and Edge Therapeutics Inc. (:) - MS Wkly - October 19th, 2019 [October 19th, 2019]
- Contrasting of BioLineRx Ltd. (BLRX) and Protalix BioTherapeutics Inc. (NYSEAMERICAN:PLX) - The Broch Herald - November 7th, 2019 [November 7th, 2019]
- BioLineRx Ltd. (BLRX)'s Financial Results Comparing With Cyanotech Corporation (NASDAQ:CYAN) - The Broch Herald - November 7th, 2019 [November 7th, 2019]
- Triple-Gene Announces Completion of Enrollment and Dosing in Phase 1 Trial of INXN-4001, First Multigenic Investigational Therapeutic Candidate for... - November 7th, 2019 [November 7th, 2019]
- Contrasting of BioLineRx Ltd. (BLRX) and Moderna Inc. (NASDAQ:MRNA) - The Broch Herald - December 3rd, 2019 [December 3rd, 2019]
- Edited Transcript of MYOK earnings conference call or presentation 11-Nov-19 1:30pm GMT - Yahoo Finance - December 3rd, 2019 [December 3rd, 2019]
- Cardiac Restoration Systems Market: Key Growth Factors and Industry Analysis 2018 - 2028 - The Market Expedition - December 3rd, 2019 [December 3rd, 2019]
- Velocity Transfer Function In The Right Pulmonary Artery And Impaired | COPD - Dove Medical Press - December 3rd, 2019 [December 3rd, 2019]
- 3 Stocks to Buy Ahead of the Next Market Crash - The Motley Fool - December 3rd, 2019 [December 3rd, 2019]
- Pulmonary Hypertension, Common in TAVR Patients, Linked to Lower Survival - TCTMD - December 3rd, 2019 [December 3rd, 2019]
- Patients With Chemotherapy-Induced Cardiomyopathy Show Improvements in LVEF After Cardiac Resynchronization Therapy - AJMC.com Managed Markets Network - December 4th, 2019 [December 4th, 2019]
- BioVentrix Announces Publication of Positive One-Year Outcomes for Revivent TC System - Yahoo Finance - December 4th, 2019 [December 4th, 2019]
- Cardiac Restoration Systems Market Forecasted To Surpass The Value Of US$ XX Mn/Bn By 2055 2017 2025 - Weekly News Times - December 13th, 2019 [December 13th, 2019]
- The Outer Line: The impact of endurance training on the cardiac health of women - VeloNews - December 13th, 2019 [December 13th, 2019]
- Contrasting of Insmed Incorporated (INSM) and BioLineRx Ltd. (NASDAQ:BLRX) - The CoinGlobalist - December 16th, 2019 [December 16th, 2019]
- CARDIAC RESTORATION SYSTEMS MARKET ANALYSIS TRENDS, GROWTH OPPORTUNITIES, SIZE, TYPE, DYNAMIC DEMAND AND DRIVES WITH FORECASTS TO 2028 - Voice of... - January 13th, 2020 [January 13th, 2020]
- Early Expressed Circulating Long Noncoding RNA CHAST is Associated with Cardiac Contractile Function in Patients with Acute Myocardial Infarction -... - January 13th, 2020 [January 13th, 2020]
- Clinical Phenogroups in Heart Failure With Preserved Ejection Fraction: Detailed Phenotypes, Prognosis, and Response to Spironolactone - DocWire News - January 23rd, 2020 [January 23rd, 2020]
- Increased Long-Term Risk for Venous Thromboembolism After Heart Failure - The Cardiology Advisor - January 23rd, 2020 [January 23rd, 2020]
- Retinoid X receptor alpha is a spatiotemporally predominant therapeutic target for anthracycline-induced cardiotoxicity - Science Advances - February 1st, 2020 [February 1st, 2020]
- Coronary Microvascular Dysfunction Found to Increase Risk for CV Events in Chronic Kidney Disease - The Cardiology Advisor - February 1st, 2020 [February 1st, 2020]
- New Data Confirms Cardiac Dimensions' Carillon System Shows Favorable Long-Term Survival Rate In Patients With Functional Mitral Regurgitation -... - February 26th, 2020 [February 26th, 2020]
- BioVentrix Announces Ralph Stephan von Bardeleben, MD, as Co- Principal Investigator of the REVIVE-HF Clinical Trial - Yahoo Finance - March 5th, 2020 [March 5th, 2020]
- Relationship between histopathological features of aspirated thrombi and long-term left ventricular function in patients with ST-segment elevation... - March 15th, 2020 [March 15th, 2020]
- FierceMedTech Names BioVentrix as One of Its "Fierce 15" Companies of 2019 - Yahoo Finance - March 15th, 2020 [March 15th, 2020]
- Causes and Prevention of Ventricular Remodeling After MI ... - March 16th, 2020 [March 16th, 2020]
- Left Ventricular Remodelling - ECR Journal - April 23rd, 2020 [April 23rd, 2020]
- Cardiac Restoration Systems Market to Make Great Impact in Near Future by 2026 - The Canton Independent Sentinel - June 12th, 2020 [June 12th, 2020]
- Multi-Society Guidelines on the Use of Multimodality CV Imaging in Competitive Athletes - The Cardiology Advisor - June 12th, 2020 [June 12th, 2020]
- Chronic PDE5i Treatment Found to Improve Cardiac Remodeling in Men, but Not Women, With Diabetic Cardiomyopathy - Endocrinology Advisor - June 12th, 2020 [June 12th, 2020]
- Acceleron to Host Conference Call and Webcast to Review Results of PULSAR Phase 2 Trial of Sotatercept Presented at American Thoracic Society 2020... - June 23rd, 2020 [June 23rd, 2020]
- American Heart Association and Barth Syndrome Foundation Partner to Address Rare Disease - PR Web - August 29th, 2020 [August 29th, 2020]
- The Association of Cardio-Ankle Vascular Index (CAVI) with Biatrial Remodeling in Atrial Fibrillation - DocWire News - September 3rd, 2020 [September 3rd, 2020]
- Cardiac Dimensions Announces Australian Therapeutic Goods Administration's Approval of the Carillon System for the Treatment of Functional Mitral... - September 3rd, 2020 [September 3rd, 2020]
- Sep 4 2020 This Week in Cardiology - Medscape - September 5th, 2020 [September 5th, 2020]
- Emerging treatment helps reverse heart failure in some patients - Science Codex - October 27th, 2020 [October 27th, 2020]
- GMAX Biopharm gives first does of anti-body drug treating PAH in phase 1B trial - PRNewswire - October 27th, 2020 [October 27th, 2020]
- North America to Outshine the Global Slowdown in Cardiac Restoration Systems market between 2020 and 2030 - The Think Curiouser - November 12th, 2020 [November 12th, 2020]
- Age-Related Development of Cardiac Remodeling and Dysfunction in Young Black and White Adults: the Coronary Artery Risk Development in Young Adults... - November 25th, 2020 [November 25th, 2020]
- Adiponectin receptor 1 variants contribute to hypertrophic cardiomyopathy that can be reversed by rapamycin - Science Advances - January 13th, 2021 [January 13th, 2021]
- Longer Survival Seen in Heart Failure Stabilized Via Cardiac Resynchronization Therapy - The Cardiology Advisor - April 13th, 2021 [April 13th, 2021]
- Cardiac Dimensions Welcomes Robert White to its Board of Directors - PRNewswire - April 13th, 2021 [April 13th, 2021]
- [Full text] SIRT1 is Required for Exercise-Induced Beneficial Effects on Myocardia | JIR - Dove Medical Press - April 13th, 2021 [April 13th, 2021]
- Role of Pyroptosis in Diabetes and Its Therapeutic Implications | JIR - Dove Medical Press - May 25th, 2021 [May 25th, 2021]
- Epigenetic therapies for heart failure | VHRM - Dove Medical Press - May 25th, 2021 [May 25th, 2021]
- Are you at risk for sudden death, and can it be prevented? - Jamaica Observer - May 25th, 2021 [May 25th, 2021]
- Does a plant-based diet improve cardiac function? Here's the answer - Hindustan Times - June 21st, 2021 [June 21st, 2021]
- Early Use of Sacubitril/Valsartan Linked to Improved Cardiac Function Post AMI - AJMC.com Managed Markets Network - November 5th, 2021 [November 5th, 2021]
- Higher BP, LV Changes Seen in Children Conceived by ART - Medscape - November 5th, 2021 [November 5th, 2021]
- Regional Heterogeneity in Determinants of Atrial Matrix Remodeling and Association with Atrial Fibrillation Vulnerability Post-Myocardial Infarction -... - January 26th, 2022 [January 26th, 2022]
- 4 promising heart failure therapies interventional cardiologists should keep an eye on - Cardiovascular Business - May 7th, 2022 [May 7th, 2022]
- LEXEO Therapeutics Announces Data Presentations at the 25th American Society of Gene & Cell Therapy (ASGCT) Annual Meeting - Yahoo Finance - May 7th, 2022 [May 7th, 2022]
- Ventricular structure and function in hypertensive patients | IJGM - Dove Medical Press - May 7th, 2022 [May 7th, 2022]
- Effects of diabetes mellitus on left ventricular function and remodeling in hypertensive patients with heart failure with reduced ejection fraction:... - May 7th, 2022 [May 7th, 2022]
- Cardior Announces CE Marking of CardiorHealth miR-132 PCR Kit Used in Ongoing HF-REVERT Phase 2 Clinical Study - Business Wire - September 12th, 2022 [September 12th, 2022]